bremelanotide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Free base; the drug product is formulated as an acetate salt |
| Molar mass | About 1025 g/mol | Calculated for the free base |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| CAS Registry Number | 189691-06-3 | Common listing for the free base |
| Typical storage | -20 °C, desiccated, protected from light | Repeated freeze-thaw cycles are best avoided |
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
Wing Commander (now Group Captain) Christopher Hugh Moran, , (5202768). Wing Commander Stephen Ronald Sims (5203336). Wing Commander Robert Adrian Williams (5204463). Civil Division Mavis Ainsworth, lately Director, School of Cultural Studies, Sheffield Hallam University. For services to Education. Edward Aldridge, , Member, Moray Council. For services to Local Government. Graeme Yorkston Alexander, Chief Executive Officer, Devro International plc. For services to the Food Industry. Anthony Paul Allen, County Trading Standards Officer, East Sussex County Council. For services to Trading Standards and to Consumer Protection. Elizabeth Anne Allen, lately Director of Nursing, North West Anglia Healthcare Trust. For services to Health Care. Ian George Allen, Valuation Principal, Board of Inland Revenue. William Claude Allington. For political and public service. Professor Richard Edward Allsop, Professor of Transport Studies, University College London. For services to Traffic Management and Road Safety. John Victor Ronald Anderson. For political service. D. Michael Archer. For services to the Advisory Board for Redundant Churches. John D. Ault, Chair, Corporation of Yeovil College. For services to Education. David Bailey, Director of Development, London Underground. For services to Public Transport in London. Professor Andrew David Bain, Board Member, Scottish Enterprise. For services to the Scottish Economy. Edward John Meldrum Ball, lately Director, Oil Companies International Marine Forum. For services to Maritime Safety to the Environment. Helen Rae Bamber.
Smoke, or any partially burnt organic matter, contains carcinogens (cancer-causing agents). The potential effects of smoking, such as lung cancer, can take up to 20 years to manifest themselves. Historically, women began smoking en masse later than men, so an increased death rate caused by smoking amongst women did not appear until later. The male lung cancer death rate decreased in 1975—roughly 20 years after the initial decline in cigarette consumption in men. A fall in consumption in women also began in 1975 but by 1991 had not manifested in a decrease in lung cancer–related mortalities amongst women. Smoke contains several carcinogenic pyrolytic products that bind to DNA and cause genetic mutations. Particularly potent carcinogens are polycyclic aromatic hydrocarbons (PAH), which are toxicated to mutagenic epoxides. The first PAH to be identified as a carcinogen in tobacco smoke was benzopyrene, which has been shown to form into an epoxide that irreversibly attaches to a cell's nuclear DNA, which may either kill the cell or cause a genetic mutation. If the mutation inhibits programmed cell death, the cell can survive to become a cancer cell. Similarly, acrolein, which is abundant in tobacco smoke, also irreversibly binds to DNA, causes mutations and thus also cancer. However, it needs no activation to become carcinogenic. There are over 19 known carcinogens in cigarette smoke. The following are some of the most potent carcinogens:
{\displaystyle {\underbrace {\ce {H-\!\!{\overset {\displaystyle R1 \atop |}{\underset {| \atop \displaystyle R2}{N}}}\!\!\!\!:}} _{\text{amine}}+\underbrace {\ce {R3-{\overset {\displaystyle O \atop \|}{C}}-OH}} _{\text{carboxylic acid}}->}\ \underbrace {\ce {{H-{\overset {\displaystyle R1 \atop |}{\underset {| \atop \displaystyle R2}{N+}}}-H}+R3-COO^{-}}} _{{\text{substituted-ammonium}} \atop {\text{carboxylate salt}}}{\ce {->[{\text{heat}}][{\text{dehydration}}]}}{\underbrace {\ce {{\overset {\displaystyle R1 \atop |}{\underset {| \atop \displaystyle R2}{N}}}\!\!-{\overset {\displaystyle O \atop \|}{C}}-R3}} _{\text{amide}}+\underbrace {\ce {H2O}} _{\text{water}}}}
When war seemed imminent, New Zealand offered its support. On 28 September 1899, Prime Minister Richard Seddon asked Parliament to approve the offer to the imperial government of a contingent of mounted rifles, thus becoming the first British Colony to send troops to the war. The British position in the dispute with the Transvaal was "moderate and righteous", he maintained. He stressed the "crimson tie" of Empire that bound New Zealand to the mother-country and the importance of a strong British Empire for the colony's security. 10 contingents of volunteers, totalling nearly 6,500 men from New Zealand, with 8,000 horses fought in the conflict, along with doctors, nurses, veterinary surgeons and school teachers. 70 New Zealanders died from enemy action, with another 158 killed accidentally or by disease. The first New Zealander killed was Farrier Bradford at Jasfontein Farm on 18 December 1899. The war was greeted with enthusiasm when the war was over, and peace greeted with patriotism and national pride. This is best shown by the fact that the Third, Fourth and Fifth contingents from New Zealand were funded by public conscription.
Sources: en.wikipedia.org
==== Supercritical CO2 ==== Food scientists have also turned to supercritical carbon dioxide (sCO2) as a means of decaffeination. Developed by Kurt Zosel, a scientist of the Max Planck Institute, it uses CO2 (carbon dioxide), heated and pressurised above its critical point, to extract caffeine. Green coffee beans are steamed and then added to a high pressure vessel. A mixture of water and CO2 is circulated through the vessel at 300 atm and 65 °C (149 °F). At this pressure and temperature CO2 is a supercritical fluid, with properties midway between a gas and a liquid. Caffeine dissolves into the CO2; but compounds contributing to the flavour of the brewed coffee are largely insoluble in CO2 and remain in the bean. In a separate vessel, caffeine is scrubbed from the CO2 with additional water. The CO2 is then recirculated to the pressure vessel. The purity of the recovered caffeine in this process is above 90%, directly from the process. The biggest industrial plant, which is producing 10,000 tons of decaffeinated coffee per year is currently in operation at Luigi Lavazza S.p.A. in Italy.
On September 18, during the second game of doubleheader against their division rivals, the Los Angeles Dodgers, with the Rockies down to their last out, trailing by a run, Helton hit a clutch two-run walk-off home run off Dodgers closer Takashi Saito, producing what may have been the most emotional moment of the regular season, turning what seemed like an imminent loss into an improbable victory, and helping propel the team toward an October run. The miracle home run kept the Rockies alive in the bid to win the wild card or perhaps even NL West title. The Rockies eventually clinched the NL wild card, in a 9–8 extra innings victory over the Padres in a wild card tie-breaker game, allowing Helton to appear in the playoffs for the first time in his career. The Rockies kept their run going into October. Having never won a playoff series in their history, the Rockies went on a rampage through the National League, winning every game they played in the NL playoffs, as they marched into the World Series. The team's first playoff opponent was the Philadelphia Phillies, who the Rockies swept in three games in the NL Division Series. Helton hit a triple on the first postseason pitch he ever faced, during the opening game of the NLDS in Philadelphia. In the second round of the playoffs, the Rockies faced the Arizona Diamondbacks, who they swept in four games of the NL Championship Series, sending the Rockies on their first trip to the World Series in franchise history.
As the Kulturkampf declined, debates about the character of the party emerged culminating in the Centre dispute, in 1906, after Julius Bachem had published the article "We must get out of the tower!" He called upon Catholic politicians to fulfill Windthorst's word and get out of their perpetual minority position by an effort to increase Protestant numbers among their representatives in parliament. His proposal was met with passionate opposition by the greater part of Catholic public, especially since it also included the Christian trade unions and other Catholic organisations. No side could win the upper hand, when the outbreak of World War I ended the dispute. After the war, there were many proposals on how the reform the party. Heinrich Brauns published the Cologne Program (Kölner Programm), which proposed the re-formation of the Zentrum under a new name (Christliche Volkspartei, CVP). This proposal was rejected, with only a few regions adopting it for the 1919 election; the party instead adopted the Berlin Guidelines (Berliner Leitsätze), which were more moderate but failed at making the Zentrum attractive for Protestant voters too. Adam Stegerwald, leader of the Christian trade unions, made another attempt at transcending the party's exclusively Catholic character and uniting Germany's fragmented party spectrum. In 1920 he advocated the formation of a broad Christian middle-party, that would transcend denominations and social classes and which could push back the Social Democrats' influence.
Sources: en.wikipedia.org
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.
Both are synthetic melanocortin agonists and share a similar peptide backbone, but they are distinct molecules with different receptor profiles. Melanotan II was never approved as a medicine, whereas bremelanotide was. Findings about one compound should not be transferred to the other without direct evidence.
It is typically distributed as a lyophilized powder in sealed vials, sometimes with a separate solvent. Purity statements usually originate from the supplier rather than an independent laboratory. Storage recommendations vary between vendors, which makes comparison across sources difficult.
It is a synthetic cyclic peptide that activates melanocortin receptors. It is given by injection and was approved in the United States in 2019 for a specific low-desire diagnosis in premenopausal women. It is not a hormonal therapy.